There are currently 113 active clinical trials seeking participants for Schizophrenia research studies. The states with the highest number of trials for Schizophrenia participants are California, Florida, Texas and New York.
Normobaric Oxygen Therapy for Individuals With First-Episode Psychosis
NCT04368039
Recruiting
Single-blind, randomized controlled trial of normobaric oxygen therapy among individuals with first-episode psychosis: Effects on symptomatology and cognition.
Gender:
All
Ages:
Between 15 years and 35 years
Trial Updated:
07/31/2023
Locations: Harding Hospital, Columbus, Ohio
Conditions: Psychosis, Schizophrenia, First-episode Psychosis
Register for Updates
CAE for Poorly Adherent Individuals With Schizophrenia
NCT06061952
Recruiting
This project aims to evaluate the feasibility, acceptability and preliminary efficacy of remotely delivered CAE among patients with schizophrenia (CAE-S).
Gender:
All
Ages:
18 years and above
Trial Updated:
01/30/2024
Locations: University Hospitals Cleveland Medical Center, Cleveland, Ohio
Conditions: Schizophrenia
Register for Updates
Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia
NCT06179108
Recruiting
This is a Phase 2, randomized, double-blind, placebo-controlled, multi-center inpatient study to evaluate the efficacy and safety of LB-102 in adult patients diagnosed with acutely exacerbated schizophrenia. To determine whether LB-102 administered to patients with acutely exacerbated schizophrenia demonstrates antipsychotic efficacy, as determined by a change from Baseline on the Positive and Negative Syndrome Scale (PANSS) total score, compared to placebo at 28 days. The secondary objectives o... Read More
Gender:
All
Ages:
Between 18 years and 55 years
Trial Updated:
06/20/2024
Locations: Pillar Clinical Research, Bentonville, Arkansas +24 locations
Conditions: Schizophrenia
Register for Updates
Journey Study: Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment for Schizophrenia
NCT05110157
Recruiting
The primary objective for this study is to evaluate the effect of adjunctive valbenazine versus placebo on symptoms of schizophrenia in participants who have inadequate response to antipsychotic treatment.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/20/2024
Locations: Neurocrine Clinical Site, Phoenix, Arizona +82 locations
Conditions: Schizophrenia
Register for Updates
Magnetic Resonance Imaging (MRI) of Neuropsychiatric Patients and Healthy Volunteers
NCT00004571
Recruiting
The purpose of this study is to use brain imaging technology to compare differences in brain structure, chemistry, and functioning in individuals with brain and mental disorders compared to healthy volunteers. Schizophrenia is a brain disorder that results from subtle changes and abnormalities in neurons. These deficits likely occur in localized regions of the brain and may result in widespread, devastating consequences. The neuronal abnormalities are inherited through a complex combination of... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/19/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Schizophrenia, Normal Physiology
Register for Updates
Brain Imaging of Childhood Onset Psychiatric Disorders, Endocrine Disorders and Healthy Volunteers
NCT00001246
Recruiting
Magnetic Resonance Imaging (MRI) unlike X-rays and CT-scans does not use radiation to create a picture. MRI use as the name implies, magnetism to create pictures with excellent anatomical resolution. Functional MRIs are diagnostic tests that allow doctors to not only view anatomy, but physiology and function. It is for these reasons that MRIs are excellent methods for studying the brain. In this study, researchers will use MRI to assess brain anatomy and function in X and Y chromosome variation... Read More
Gender:
All
Ages:
3 years and above
Trial Updated:
06/19/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Schizophrenia, Attention Deficit Disorder With Hyperactivity, Attention Deficit Hyperactivity Disorder
Register for Updates
Inpatient Evaluation of Adults With Schizophrenia
NCT00001247
Recruiting
The purpose of this study is to understand the biologic basis of schizophrenia and to determine which symptoms are related to the illness itself and which are related to medications used to treat the illness. Schizophrenia and related psychoses are chronic brain disorders whose prognosis is often poor and whose pathophysiology remains obscure. Brain imaging technologies such s positron emission tomography (PET), functional magnetic resonance imaging (fMRI), and magnetic resonance imaging (MRI)... Read More
Gender:
All
Ages:
Between 18 years and 120 years
Trial Updated:
06/19/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Schizophrenia
Register for Updates
A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia
NCT05145413
Recruiting
This is a Phase 3, 6-week, randomized, double-blind, placebo-controlled, multicenter, outpatient study in subjects with schizophrenia with an inadequate response to their current atypical antipsychotic treatment. The primary objective of the study is to assess the efficacy of adjunctive KarXT (a fixed dose combination of xanomeline and trospium chloride twice daily [BID]) versus placebo in the treatment of subjects with inadequately controlled symptoms of schizophrenia as measured by the Positiv... Read More
Gender:
All
Ages:
Between 18 years and 59 years
Trial Updated:
06/17/2024
Locations: Clinical Trial Site, Phoenix, Arizona +83 locations
Conditions: Schizophrenia
Register for Updates
CLOZAPINE Response in Biotype-1
NCT04580134
Recruiting
The CLOZAPINE study is designed as a multisite study across 5 sites and is a clinical trial, involving human participants who are prospectively assigned to an intervention. The study will utilize a stringent randomized, double-blinded, parallel group clinical trial design. B2 group will serve as psychosis control with risperidone as medication control. The study is designed to evaluate effect of clozapine on the B1 participants, and the effect that will be evaluated is a biomedical outcome. The... Read More
Gender:
All
Ages:
Between 18 years and 60 years
Trial Updated:
06/17/2024
Locations: UT Southwestern Medical Center, Dallas, Texas
Conditions: Schizophrenia, Schizoaffective Disorder, Bipolar 1 Disorder
Register for Updates
Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder
NCT04578756
Recruiting
The purpose of this study is to evaluate the long-term safety and tolerability of cariprazine in the treatment of pediatric participants with schizophrenia, bipolar I disorder, or autism spectrum disorder (ASD) and to establish the benefit-risk profile of long-term treatment in this population.
Gender:
All
Ages:
Between 5 years and 17 years
Trial Updated:
06/12/2024
Locations: Harmonex Neuroscience Research /ID# 234938, Dothan, Alabama +41 locations
Conditions: Schizophrenia, Bipolar I Disorder, Autism Spectrum Disorder (ASD)
Register for Updates
A Study to Test Long-term Safety of Iclepertin in People With Schizophrenia Who Took Part in a Previous CONNEX Study
NCT05211947
Recruiting
This study is open to adults with schizophrenia who took part in a previous CONNEX study (study 1346-0011, 1346-0012, or 1346-0013). The purpose of this study is to find out how well people with schizophrenia can tolerate a medicine called Iclepertin in the long term. Participants take Iclepertin as tablets once a day for 1 year. In addition, all participants take their normal medication for schizophrenia. Participants are in the study for a little more than 1 year. During this time, they visi... Read More
Gender:
All
Ages:
Between 18 years and 51 years
Trial Updated:
06/11/2024
Locations: Advanced Research Center, Inc., Anaheim, California +248 locations
Conditions: Schizophrenia
Register for Updates
PET Scanning in Parkinson s Disease
NCT00024622
Recruiting
This is an in vivo positron emission tomography (PET) study of regional cerebral dopamine and blood flow in normal volunteers, persons with Parkinson s disease (both familial and sporadic), and those with schizophrenia spectrum disorders. The latter also sign consent for NIH approved protocol 89-M-0160, "Inpatient Evaluation of Neuropsychiatric Patients," PI: Daniel Eisenberg, M.D. Using PET with 6-[F-18] Fluoro-L-dopa (FDOPA) and (15)0-H2O in a single scan session, both presynaptic dopaminergic... Read More
Gender:
All
Ages:
Between 18 years and 90 years
Trial Updated:
06/06/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Schizophrenia, Parkinson's Disease
Register for Updates